Hundreds of people across England living with multidrug-resistant HIV will soon have access to lenacapavir, a breakthrough HIV treatment. The decision, announced by the NHS this week, has been welcomed by HIV campaigners who had been calling for this because lenacapavir will be life-saving for many people living with HIV in the UK who have run out of other treatment options.
But as lenacapavir is rolled out here in England, there are many across the rest of the world who do not have access to this treatment, including the very communities who hosted clinical trials and helped make the drug possible. How did this happen?
